Study reveals how melanoma silences the skin's natural antitumor defense
Melanoma exosomal hsa‑miR‑221‑5p suppresses keratinocyte LL‑37 to promote tumor progression
Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL‑37 to promote tumor progression
The study identifies a novel mechanism by which melanoma cells use exosomal microRNA to downregulate the antimicrobial peptide LL‑37 in surrounding keratinocytes, thereby weakening an innate skin defense that normally restrains tumor growth. Targeting this exosomal pathway or boosting LL‑37 could provide new therapeutic or biomarker strategies for melanoma treatment.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies